呋喹替尼联合信迪利单抗治疗晚期实体瘤的1b/2期试验:剂量递增及剂量扩展阶段的转移性结直肠癌队列
这项1b/2期开放标签多中心多队列研究评估呋喹替尼联合信迪利单抗治疗晚期实体瘤的安全性、耐受性和初步疗效。剂量递增组23例,mCRC扩展组37例, pooled分析44例接受信迪利单抗Q3W的mCRC患者。推荐2期剂量下mCRC的ORR为23.8%,中位PFS 6.9个月,OS 14.8个月。
要点
- 剂量递增阶段发生1例剂量限制性毒性(3级肌钙蛋白T升高)。
- 剂量递增组和 pooled mCRC分析中≥3级治疗相关不良事件发生率分别为43.5%和47.7%。
- 推荐2期剂量下mCRC的ORR为23.8%,中位PFS 6.9个月,OS 14.8个月。
核心结论
- 呋喹替尼联合信迪利单抗在晚期实体瘤患者中耐受良好,并在mCRC中显示出有前景的疗效。
研究设计与样本
- 1b/2期、开放标签、多中心、多队列剂量递增和剂量扩展研究,纳入晚期实体瘤(剂量递增)或mCRC(剂量扩展的一个队列)患者。
- 剂量递增组23例,mCRC扩展队列37例,其中接受信迪利单抗Q3W的44例mCRC患者被 pooled分析。
主要发现
- 剂量递增阶段发生1例剂量限制性毒性(3级肌钙蛋白T升高)。
- 剂量递增组≥3级治疗相关不良事件发生率为43.5%, pooled mCRC分析为47.7%。
- 推荐2期剂量(呋喹替尼5 mg每日一次,用2周停1周,联合信迪利单抗200 mg Q3W)下, pooled mCRC分析的ORR为23.8%(95% CI 8.2-47.2),中位PFS为6.9个月(95% CI 5.4-8.3),OS为14.8个月(95% CI 8.8-未达到)。
- 错配修复功能完整mCRC患者的ORR为20.0%(95% CI 4.3-48.1),中位PFS为6.9个月(95% CI 4.8-10.1),OS为20.0个月(95% CI 8.1-未达到)。
关键数值与推荐
- 推荐2期剂量为呋喹替尼5 mg每日一次,用2周停1周,联合信迪利单抗200 mg Q3W。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fruquintinib (anti-vascular endothelial growth factor 1/2/3) plus sintilimab (anti-programmed death-1) demonstrated enhanced anti-tumour effects versus monotherapy in a preclinical study. We investigated the combination in patients with advanced solid tumours, including metastatic colorectal cancer (mCRC). METHODS: In this phase 1b/2, open-label, multi-centre, multi-cohort dose-escalation and dose-expansion study, patients with advanced solid tumours (dose-escalation) or mCRC (one cohort in dose-expansion) received different doses of fruquintinib plus a fixed dose of sintilimab once every 4 weeks (Q4W) or 3 weeks (Q3W). Primary objectives were safety, tolerability, and the preliminary efficacy. This study is registered at ClinicalTrials.gov, NCT03903705. FINDINGS: By the data cut-off date (30th December 2021), 23 patients were enrolled in the dose-escalation and 37 patients in the mCRC cohort of the dose-expansion; 44 patients with mCRC who received sintilimab Q3W were pooled for analysis. One dose-limiting toxicity event (grade 3 troponin T increased) occurred during the dose escalation. Grade ≥3 treatment-related adverse events occurred in 43.5% and 47.7% of patients in the dose-escalation phase and pooled mCRC analysis, respectively. Among patients treated with the recommended phase 2 dose (fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus sintilimab 200 mg Q3W) in pooled mCRC analysis, the objective response rate was 23.8% (95% CI 8.2-47.2), median progression-free survival was 6.9 months (95% CI 5.4-8.3), and overall survival was 14.8 months (95% CI 8.8-not reached); in patients with mismatch repair-proficient mCRC, these were 20.0% (95% CI 4.3-48.1), 6.9 months (95% CI 4.8-10.1), and 20.0 months (95% CI 8.1-not reached), respectively. INTERPRETATION: Fruquintinib plus sintilimab was well tolerated in patients with advanced solid tumours and showed promising efficacy in mCRC.
引用
- Guo Y, Zhang W, Ying J, et al. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. Eur J Cancer. 2022. PMID: 36628898. doi:10.1016/j.ejca.2022.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。